Skip to content

MDMA-Assisted Therapy for Posttraumatic Stress Disorder: A Mixed-Methods Case Study of a Participant of Color From an Open-Label Trial

Terence H. W. Ching, Monnica T. Williams, Sara Reed, M. Kisicki, Julie B. Wang, B. Yazar-Klosinski, A. Emerson, R. Doblin

Journal of Humanistic Psychology February 10, 2022 DOI: 10.1177/00221678221076993 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Mixed-methods case study Open-label Case report Peer reviewed
Sample size 1
Population Participant of color with treatment-resistant PTSD from an open-label trial of MDMA-AT
Intervention MDMA-assisted therapy
Topics MDMA PTSD
Citations 10
Key findings A participant of color with treatment-resistant PTSD showed quantitative improvement in symptoms and reported psychological mechanisms of change, reduced PTSD symptoms, and additional effects beyond symptom reduction during MDMA-assisted therapy.

Abstract

MDMA (±3,4-methylenedioxymethamphetamine)-assisted therapy (MDMA-AT) was shown in previous clinical trials to have promising efficacy and safety for alleviating treatment-resistant posttraumatic stress disorder (PTSD). However, due to low ethnoracial diversity, the question remains as to whether ethnoracial minority participants would benefit similarly. Thus, a mixed-methods case study was conducted on a participant of color from an open-label trial of MDMA-AT for PTSD to provide a culturally informed lens on symptom recovery with this treatment approach. An additional aim was to elucidate mechanisms of change underlying this treatment for the participant. A case profile was provided, documenting quantitative improvement in PTSD symptoms. This was followed by an interpretative phenomenological analysis (IPA) of effects and mechanisms of action for this participant, based on integration session transcripts. Results of IPA indicated recurrent themes related to psychological mechanisms of symptom change, reduced PTSD symptoms, and additional effects (positive and negative) beyond PTSD symptom reduction. These themes were discussed and recommendations for attuning to culturally relevant material during MDMA-AT were provided.

Comparable studies

Other case reports and case series on MDMA for PTSD, most cited first.

Study Year Design Participants
Combining Cognitive-Behavioral Conjoint Therapy for PTSD with 3,4-Methylenedioxymethamphetamine (MDMA): A Case Example. One couple with PTSD and a severe trauma history, participating in a pilot trial... 2019 Case study n = 2
MDMA, Internal Family Systems therapy, and the Minnesota model in the resolution of C-PTSD-induced alcohol and diazepam addiction—A retrospective case study Man in his forties with alcohol and diazepam addiction and complex PTSD from childhood... 2023 Case study n = 1
New‐Onset Obsessive–Compulsive Symptoms After MDMA‐Assisted Psychotherapy in a Patient With Refractory PTSD: A Case Report 31-year-old woman with chronic PTSD, nondistressing childhood compulsions, and complex... 2026 Case study n = 1
Six Month Follow up of the one of the First Patients to Complete MDMA-Assisted Therapy for PTSD Outside of Clinical Trials in Australia: Implications for Translating Clinical Research to Clinical Practice Adult female with chronic PTSD, depression, and anxiety due to domestic violence 2024 Case report n = 1

Explore topics

By condition and practice